YL202 + toripalimab

YL202 + toripalimab is a combination therapy comprising **YL202** (also known as BNT326), a HER3-targeted antibody-drug conjugate (ADC), and **toripalimab**, a monoclonal antibody against programmed cell death protein 1 (PD-1). YL202 targets and delivers cytotoxic payload to cells expressing HER3, which is overexpressed in various tumors, resulting in selective tumor cell killing. Toripalimab is a checkpoint inhibitor that blocks PD-1, enhancing T-cell-mediated antitumor immunity. This combination is in clinical investigation for advanced solid tumors, including non-small cell lung cancer and breast cancer, aiming to leverage both targeted cytotoxicity and immune checkpoint blockade[4][7].